Lethal midline granuloma arises from
**Core Concept**
Lethal midline granuloma, also known as natural killer/T-cell lymphoma, is a rare and aggressive form of non-Hodgkin lymphoma that primarily affects the nasal cavity, sinuses, and other midline structures of the face. It is characterized by a proliferation of cytotoxic T cells and natural killer cells, which leads to tissue destruction and necrosis.
**Why the Correct Answer is Right**
The correct answer is **NK/T-cell lymphoma**. This condition arises from a clonal expansion of natural killer cells and cytotoxic T cells, which are a type of lymphocyte that plays a key role in the immune system's ability to recognize and destroy infected cells or tumor cells. The pathogenesis of NK/T-cell lymphoma involves the abnormal activation of NK cells and T cells, leading to an excessive release of cytokines and other inflammatory mediators that cause tissue damage and necrosis.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because while **Hodgkin lymphoma** is a type of lymphoma, it is characterized by the presence of Reed-Sternberg cells and is typically less aggressive than NK/T-cell lymphoma.
**Option B:** This option is incorrect because **Nasal angiofibroma** is a benign tumor that arises from the nasal cavity, but it is not a form of lymphoma and does not have the same aggressive behavior as NK/T-cell lymphoma.
**Option C:** This option is incorrect because **Squamous cell carcinoma** is a type of cancer that arises from the squamous epithelium, but it is not typically associated with the midline structures of the face and is not a type of lymphoma.
**Clinical Pearl / High-Yield Fact**
NK/T-cell lymphoma is often associated with a poor prognosis, and early diagnosis is critical for improving outcomes. Patients with NK/T-cell lymphoma may present with symptoms such as nasal obstruction, epistaxis, and facial pain, and may require a combination of chemotherapy, radiation therapy, and surgery for treatment.
**Correct Answer: D. NK/T-cell lymphoma**